HDR syndrome

What's on this Page

HDR Syndrome: A Comprehensive Medical Review

Introduction

HDR syndrome, also known as Barakat syndrome or hypoparathyroidism-sensorineural deafness-renal disease syndrome, is an extremely rare autosomal dominant genetic disorder first described by Ali J. Barakat and colleagues in 1977. According to trusted medical organizations including Orphanet, the National Organization for Rare Disorders (NORD), and the National Institutes of Health (NIH), this condition is characterized by the classic triad of Hypoparathyroidism, sensorineural Deafness, and Renal disease. The syndrome derives its name from these three cardinal features and represents a distinct clinical entity caused by haploinsufficiency of the GATA3 gene located on chromosome 10p14-15.^[1]^[2]^[3]^[4]

Definition and Classification

Disease Definition

According to Orphanet, the European reference portal for rare diseases, HDR syndrome is defined as “a rare, clinically heterogeneous genetic disorder characterized by the triad of hypoparathyroidism (H), sensorineural deafness (D) and renal disease (R)”. The condition is classified under multiple medical taxonomies:^[1]

OMIM Classification: #146255 (Hypoparathyroidism-sensorineural deafness-renal disease syndrome)
Orphanet Code: ORPHA:2237
Alternative Names: Barakat syndrome, Hypoparathyroidism-deafness-renal dysplasia syndrome

Synonyms and Nomenclature

The condition is known by several names in medical literature:^[2]^[3]^[1]

HDR syndrome
Barakat syndrome
Hypoparathyroidism-sensorineural deafness-renal disease syndrome
Hypoparathyroidism-deafness-renal dysplasia syndrome
GATA3 haploinsufficiency syndrome

Epidemiology and Demographics

Prevalence and Geographic Distribution

HDR syndrome is considered one of the rarest genetic endocrine disorders:

Global Prevalence: According to Orphanet and recent literature reviews, the exact prevalence is unknown, but the syndrome is considered extremely rare. By 2018, approximately 180 individuals from different racial and ethnic groups had been reported in the worldwide medical literature.^[4]^[1]

Recent Case Reports: Since 2018, at least six additional case reports have been published, bringing the total documented cases to fewer than 200 worldwide.^[4]

Geographic Distribution: The syndrome has a worldwide distribution with no specific ethnic or geographic clustering, affecting patients of diverse racial and ethnic backgrounds.^[5]^[1]

Demographic Characteristics

Age at Presentation: HDR syndrome may present at any age, from neonatal period to adulthood:^[1]^[4]

Prenatal detection: Congenital kidney and urinary tract anomalies may be detected on routine prenatal ultrasonography
Early childhood: Often presents with deafness, hypocalcemia, tetany, or seizures
Late diagnosis: Some patients are not diagnosed until adulthood, as demonstrated by cases diagnosed decades after initial presentation ^[4]

Gender Distribution: The condition affects both males and females equally, consistent with its autosomal dominant inheritance pattern.^[5]^[1]

Family History: Given the autosomal dominant inheritance with variable penetrance, affected individuals may have one affected parent, though de novo mutations can occur.^[6]^[7]

Pathophysiology and Molecular Mechanisms

Genetic Basis

GATA3 Gene Mutations: HDR syndrome is primarily caused by heterozygous mutations in the GATA3 gene located on chromosome 10p14-15. The GATA3 gene encodes a dual zinc-finger transcription factor belonging to the GATA family of transcription factors.^[8]^[9]^[1]

Gene Structure: The GATA3 gene consists of six exons and encodes a 444-amino acid transcriptional factor containing:^[6]^[5]

Two N-terminal transactivating domains (TA1 and TA2)
Two C-terminal zinc finger domains (ZnF1 and ZnF2)
ZnF1 stabilizes DNA binding and facilitates protein-protein interactions
ZnF2 is essential for DNA binding specificity

Mutation Spectrum: More than 50 GATA3 mutations have been reported in patients with HDR syndrome, including:^[9]^[6]^[5]

Large deletions removing the entire GATA3 gene
Small insertions and deletions (indels)
Missense and nonsense mutations
Frameshift mutations
Splice site mutations

Molecular Pathophysiology

GATA3 Function: The GATA3 transcription factor plays crucial roles in vertebrate embryonic development of multiple organ systems:^[1]^[4]

Parathyroid glands: Essential for parathyroid gland development and function
Auditory system: Required for inner ear development and hair cell function
Kidneys: Critical for renal development and nephron formation
Thymus: Important for T-cell development
Central nervous system: Involved in neural crest cell development

Haploinsufficiency Mechanism: HDR syndrome results from GATA3 haploinsufficiency, where one functional copy of the gene is insufficient to maintain normal development and function of target organs.^[5]^[4]^[1]

Developmental Impact: The loss of GATA3 function affects multiple developmental pathways:

Parathyroid dysgenesis: Impaired parathyroid gland development leading to hypoparathyroidism
Otic vesicle abnormalities: Defective inner ear development causing sensorineural hearing loss
Nephron defects: Abnormal kidney development resulting in various renal anomalies

Clinical Manifestations

The HDR Triad

The syndrome’s name reflects its three cardinal features, though phenotypic heterogeneity is significant:^[4]^[1]

H – Hypoparathyroidism

Prevalence and Clinical Features: Occurs in approximately 93% of patients:^[1]

Hypocalcemia: Low serum calcium levels (typically <8.5 mg/dL or 2.1 mmol/L)
Hyperphosphatemia: Elevated serum phosphate levels
Low or inappropriately normal PTH: Deficient parathyroid hormone production
Clinical symptoms: Tetany, muscle cramps, seizures, neuromuscular irritability

Age of Presentation:^[10]^[11]^[12]

Can present from infancy to adulthood
May be the first manifestation in some patients
Symptoms range from mild hypocalcemia to severe seizures

D – Sensorineural Deafness

Prevalence and Characteristics: Occurs in approximately 96% of patients:^[5]^[1]

Bilateral involvement: Usually affects both ears
Severity range: From moderate to profound impairment
Early onset: Often the earliest and most consistent feature
High-frequency predominance: Typically affects higher frequencies more severely

Audiological Features:^[11]^[5]

Congenital or early-onset: May be present from birth
Progressive: Can worsen over time
Outer hair cell dysfunction: Evidence suggests malfunctioning of outer hair cells
Absence of otoacoustic emissions: Indicating cochlear dysfunction

R – Renal Disease

Prevalence and Spectrum: Occurs in approximately 72% of patients:^[13]^[1]

Structural Abnormalities:^[11]^[13]^[1]

Renal dysplasia: Abnormal kidney development
Renal hypoplasia or aplasia: Small or absent kidneys
Cystic kidneys: Multiple renal cysts
Pelvicalyceal deformity: Abnormal collecting system structure
Vesicoureteral reflux: Backward flow of urine from bladder to kidneys

Functional Abnormalities:^[14]^[11]

Chronic kidney disease: Progressive decline in renal function
Nephrotic syndrome: Protein loss in urine
Hematuria: Blood in urine
Proteinuria: Protein in urine
Nephrocalcinosis: Calcium deposition in kidneys
Renal failure: May progress to end-stage renal disease

Associated Clinical Features

Additional Manifestations

Cardiac Abnormalities:^[1]

Congenital heart disease in some patients
Various structural cardiac defects

Neurological Features:^[11]

Basal ganglia calcifications: Intracranial calcium deposits
Seizures: Due to hypocalcemia
Cognitive disability: In some patients
Developmental delays: May occur in severely affected individuals

Ophthalmological Manifestations:^[1]

Retinitis pigmentosa: Rare association
Nystagmus: Involuntary eye movements
Pseudopapilledema: Optic disc swelling

Other Features:^[11]^[1]

Growth failure: Poor linear growth in some patients
Psoriasis: Skin manifestation in rare cases
Facial dysmorphism: Including bulbous nose, long philtrum, thin upper lip
Genitourinary abnormalities: Such as bicornuate uterus

Diagnostic Approach

Clinical Diagnosis

The diagnosis of HDR syndrome is based on clinical findings and genetic confirmation:^[4]^[1]

Diagnostic Criteria: According to current guidelines:^[1]

Complete HDR triad: Present in only 65% of patients
Partial phenotypes: Various combinations of H, D, and R features
- HD: 27.2% of patients
- DR: 4.4% of patients
- HR: 1.7% of patients
- Isolated R: 1.7% of patients
- Isolated D: 0.6% of patients

Confirmation Criteria:^[1]

Patients with the complete HDR triad, OR
Two out of three features plus positive family history, OR
Isolated deafness or renal disease with positive GATA3 testing

Laboratory Investigations

Biochemical Assessment

Calcium-Phosphate Metabolism:^[10]^[14]^[11]

Serum calcium: Low (typically <2.1 mmol/L or 8.5 mg/dL)
Serum phosphate: Elevated (>1.6 mmol/L or 5.0 mg/dL)
Intact PTH: Low or inappropriately normal (<15-20 pg/mL)
25-hydroxyvitamin D: May be deficient
1,25-dihydroxyvitamin D: Often normal or elevated
Serum magnesium: Should be checked and corrected if low

Renal Function Assessment:^[14]^[11]

Serum creatinine: May be elevated
Blood urea nitrogen: Often increased
Estimated GFR: May show reduced kidney function
Urinalysis: May show hematuria, proteinuria
24-hour urine: Calcium and protein excretion assessment

Genetic Testing

GATA3 Gene Analysis:^[7]^[9]^[4]

Next-generation sequencing: Comprehensive gene analysis
Targeted gene sequencing: Focus on GATA3 coding regions
Copy number analysis: Detection of large deletions
Functional studies: Assessment of mutation effects when indicated

Family Studies:^[5]

Cascade testing: Evaluation of at-risk family members
Segregation analysis: Confirmation of mutation inheritance
Genetic counseling: Essential for family planning

Imaging Studies

Audiological Assessment

Hearing Evaluation:^[12]^[5]

Pure tone audiometry: Comprehensive hearing assessment
Brainstem evoked response audiometry (BERA): Objective hearing testing
Otoacoustic emissions: Assessment of outer hair cell function
Tympanometry: Middle ear function evaluation

Renal Imaging

Kidney Assessment:^[13]^[11]

Renal ultrasonography: First-line imaging for structural abnormalities
CT urography: Detailed assessment of urinary tract anatomy
MRI: When indicated for complex cases
Nuclear medicine studies: Assessment of differential renal function
Voiding cystourethrography: Evaluation for vesicoureteral reflux

Additional Imaging

Neurological Imaging:^[11]

Brain CT: Detection of intracranial calcifications
Brain MRI: Assessment of structural abnormalities

Cardiac Evaluation:^[1]

Echocardiography: Assessment for congenital heart disease
ECG: Evaluation for QT prolongation due to hypocalcemia

Prenatal Diagnosis

Antenatal Detection:^[1]

Fetal ultrasonography: May detect renal abnormalities
Genetic testing: Available for families with known mutations
Fetal hearing assessment: Limited prenatal evaluation possible

Differential Diagnosis

Primary Considerations

DiGeorge Syndrome (22q11.2 Deletion Syndrome)

Similarities and Differences:

Similarities: Hypoparathyroidism, hearing loss, renal abnormalities
Key differences:
- Cardiac defects: More common and severe in DiGeorge syndrome
- Immunodeficiency: Present in DiGeorge, absent in HDR
- Facial features: More characteristic in DiGeorge syndrome
- Genetic basis: 22q11.2 deletion vs. GATA3 mutations

Isolated Hypoparathyroidism

Distinguishing Features:^[4]

Hearing: Normal hearing in isolated forms
Renal function: Normal kidney structure and function
Family history: Different inheritance patterns
Genetic testing: Mutations in other genes (PTH, CaSR, etc.)

CHARGE Syndrome

Clinical Overlap:

Hearing loss: Common in both conditions
Renal abnormalities: May occur in CHARGE
Key differences: CHD7 mutations, coloboma, heart defects in CHARGE

Secondary Considerations

Other Genetic Hypoparathyroidism Syndromes:

Autoimmune polyendocrinopathy syndrome: Associated with other autoimmune features
Mitochondrial disorders: May include hearing loss and renal dysfunction
Kenny-Caffey syndrome: Growth retardation, cortical thickening of bones

Acquired Causes:

Surgical hypoparathyroidism: History of neck surgery
Autoimmune hypoparathyroidism: Anti-parathyroid antibodies
Infiltrative diseases: Hemochromatosis, Wilson’s disease

Treatment and Management

Acute Management

Hypocalcemic Crisis

Emergency Treatment:^[15]^[14]

Intravenous calcium gluconate: 10-20 mL of 10% solution in 50-100 mL normal saline
Infusion rate: 1-2 mg/kg/hour of elemental calcium
Monitoring: Continuous cardiac monitoring due to risk of arrhythmias
Magnesium correction: Essential if hypomagnesemia is present

Seizure Management:^[12]

Calcium replacement: Primary treatment for hypocalcemic seizures
Avoid anticonvulsants: Unless calcium correction is insufficient
Supportive care: Airway protection, monitoring

Long-term Management

Calcium and Vitamin D Therapy

Standard Treatment Protocol:^[16]^[15]^[14]

Calcium Supplementation:

Calcium carbonate: 1-3 grams elemental calcium daily in divided doses
Calcium citrate: Alternative for patients with absorption issues
Dosing: Typically 1.0-2.4 g/day elemental calcium

Active Vitamin D Analogues:^[15]^[14]

Calcitriol (1,25-dihydroxyvitamin D3): 0.25-2.0 μg daily in divided doses
Alfacalcidol (1α-hydroxyvitamin D3): Alternative option
Paricalcitol: May be used in some patients

Dosing Considerations in HDR Syndrome:^[14]

Lower doses required: HDR patients typically need lower doses than other hypoparathyroidism patients
Calcium carbonate: 500 mg-2 g daily
Calcitriol: 0.25-1.25 μg daily
Risk of hypercalciuria: Close monitoring required

Monitoring and Follow-up

Laboratory Monitoring:^[15]^[14]

Serum calcium: Target 8.0-9.5 mg/dL (2.0-2.4 mmol/L)
Serum phosphate: Monitor for normalization
24-hour urine calcium: Keep <300-400 mg/day to prevent nephrolithiasis
Kidney function: Regular assessment of creatinine and eGFR
Frequency: Every 3-6 months once stable

Complications to Monitor:^[14]^[15]

Hypercalciuria: Risk of nephrolithiasis and nephrocalcinosis
Hypercalcemia: From overtreatment
Progressive renal disease: Regular nephrology follow-up
Cardiovascular effects: ECG monitoring

Supportive Care

Audiological Management

Hearing Support:^[5]

Hearing aids: Amplification devices for moderate hearing loss
Cochlear implants: For severe to profound sensorineural hearing loss
Educational support: Special education services when needed
Communication training: Sign language, lip reading

Renal Care

Nephrology Management:^[14]

Blood pressure control: ACE inhibitors or ARBs when indicated
Proteinuria management: Treatment to reduce protein loss
Chronic kidney disease care: Management of complications
Renal replacement therapy: Dialysis or transplantation for end-stage disease

Prognosis of Renal Disease:^[14]

Progressive nature: Many patients develop chronic kidney disease
End-stage renal failure: Approximately 9% require renal replacement therapy
Early intervention: Important for preserving kidney function

Genetic Counseling

Family Planning:^[4]

Inheritance pattern: Autosomal dominant with variable penetrance
Recurrence risk: 50% for each pregnancy
Prenatal testing: Available for families with known mutations
Family screening: Evaluation of at-risk relatives

Prognosis and Natural History

Disease Course

Variable Phenotype: The clinical course of HDR syndrome is highly variable, even within the same family:^[4]^[1]

Factors Affecting Prognosis:^[14]

Severity of renal disease: Most important prognostic factor
Degree of hearing loss: Impacts quality of life and development
Adequacy of calcium management: Affects long-term complications
Early diagnosis: Enables appropriate treatment and monitoring

Long-term Outcomes

Renal Prognosis:^[14]

Progressive chronic kidney disease: Common long-term complication
End-stage renal failure: Develops in approximately 9% of patients
Renal replacement therapy: May require dialysis or transplantation
Hypertension: Common complication requiring management

Hearing Outcomes:^[5]

Progressive hearing loss: May worsen over time
Early intervention: Hearing aids and educational support improve outcomes
Cochlear implants: Can be effective for severe hearing loss

Calcium-Related Complications:^[15]^[14]

Nephrolithiasis: Risk from hypercalciuria
Nephrocalcinosis: Calcium deposition in kidneys
Cardiovascular effects: From chronic hypocalcemia or hypercalcemia
Cataracts: May develop from chronic hypocalcemia

Quality of Life Considerations

Functional Impact:

Educational needs: Due to hearing loss
Social development: Impact of hearing impairment
Employment: Generally good prospects with appropriate support
Family planning: Genetic counseling considerations

Genetic Counseling and Reproductive Considerations

Inheritance Pattern and Risk Assessment

Autosomal Dominant Inheritance:^[4]^[1]

Penetrance: Variable expression within families
Anticipation: Some evidence of genetic anticipation with earlier and more severe presentation in subsequent generations ^[7]^[5]
De novo mutations: Can occur, accounting for some sporadic cases

Recurrence Risk:^[4]

Affected parent: 50% risk for each pregnancy
Unaffected parents with de novo mutation: Low recurrence risk
Family planning: Comprehensive genetic counseling essential

Prenatal and Preimplantation Diagnosis

Prenatal Testing Options:

Genetic testing: Available for families with known GATA3 mutations
Ultrasound screening: May detect renal abnormalities
Counseling: Comprehensive discussion of options and implications

Preimplantation Genetic Diagnosis:

In vitro fertilization: Required for PGD
Embryo selection: Testing embryos before implantation
Success rates: Variable depending on specific mutations

Research and Future Directions

Current Research Areas

Pathophysiology Studies:^[9]

GATA3 function: Understanding normal and abnormal transcription factor activity
Genotype-phenotype correlations: Relating specific mutations to clinical severity
Developmental biology: Role of GATA3 in organ development
Modifier genes: Factors influencing variable expression

Clinical Research:

Natural history studies: Long-term outcome assessment
Treatment optimization: Improved management protocols
Biomarker development: Indicators of disease progression
Quality of life research: Patient-reported outcomes

Emerging Technologies

Therapeutic Development:

Gene therapy: Potential future treatment approaches
Pharmacological interventions: Drugs targeting GATA3 pathways
Regenerative medicine: Tissue engineering applications
Precision medicine: Personalized treatment strategies

Diagnostic Advances:

Improved genetic testing: Better mutation detection methods
Functional assays: Assessment of protein function
Biomarker discovery: Non-invasive monitoring tools
Prenatal diagnosis: Enhanced early detection methods

Global Health Perspectives

Healthcare Access and Management

Developed Countries:

Specialized centers: Access to multidisciplinary teams
Genetic services: Comprehensive testing and counseling
Advanced treatments: Cochlear implants, renal replacement therapy
Research participation: Opportunities for clinical studies

Resource-Limited Settings:

Diagnostic challenges: Limited genetic testing availability
Basic management: Focus on calcium and vitamin D supplementation
Hearing support: Limited access to advanced audiological interventions
International collaboration: Telemedicine and expert consultation

Public Health Implications

Awareness and Education:

Healthcare provider training: Recognition of rare syndrome features
Patient advocacy: Support groups and educational resources
Research funding: Investment in rare disease research
International registries: Global data collection efforts

Recent Case Reports and Clinical Insights

Novel Mutations and Phenotypes

Recent Genetic Discoveries:^[17]^[7]

Splice site mutations: c.1050+2T>C causing incorrect splicing
Frameshift mutations: Various deletions and insertions
Missense mutations: Affecting protein function
Large deletions: Involving entire GATA3 gene

Phenotypic Variability:^[6]^[11]

Isolated presentations: Hearing loss without other features
Associated anomalies: Hirschsprung disease in rare cases ^[18]
Late-onset presentations: Diagnosis in elderly patients ^[4]
Atypical features: Cataracts, cardiac abnormalities

Treatment Insights

Dosing Observations:^[14]

Lower vitamin D requirements: HDR patients need less active vitamin D than typical hypoparathyroidism
Hypercalciuria risk: Increased susceptibility to calcium overload
Individual variation: Significant differences in treatment response
Monitoring importance: Close follow-up prevents complications

Conclusion

HDR syndrome represents a fascinating example of how mutations in a single transcription factor gene can result in a complex multisystem disorder affecting calcium homeostasis, hearing, and kidney development. As one of the rarest genetic endocrine disorders, with fewer than 200 documented cases worldwide, it challenges our understanding of GATA3 biology and provides unique insights into the developmental roles of this crucial transcription factor.

The syndrome’s pathophysiology, rooted in GATA3 haploinsufficiency, demonstrates the critical importance of this zinc-finger transcription factor in multiple developmental pathways. The variable penetrance and phenotypic heterogeneity observed in HDR syndrome highlight the complex relationships between genetic dosage, developmental timing, and organ-specific gene expression patterns.

From a clinical perspective, the diagnostic challenge of HDR syndrome lies in its phenotypic variability, with only 65% of patients presenting with the complete triad. The recognition that hearing loss is the most consistent feature, present in 96% of patients, emphasizes the importance of audiological evaluation in patients with unexplained hypoparathyroidism or renal disease. The growing awareness of isolated presentations and the availability of genetic testing have improved diagnostic capabilities and enabled earlier recognition of affected individuals.

The management of HDR syndrome requires a multidisciplinary approach, with particular attention to the unique characteristics of hypoparathyroidism in this condition. The observation that HDR patients typically require lower doses of active vitamin D compared to other forms of hypoparathyroidism is clinically significant and may relate to residual parathyroid function or altered vitamin D metabolism. The high risk of hypercalciuria and subsequent nephrocalcinosis underscores the importance of careful monitoring and individualized dosing.

The renal prognosis in HDR syndrome is particularly concerning, with approximately 9% of patients progressing to end-stage renal disease requiring renal replacement therapy. This highlights the importance of early nephrology involvement and regular monitoring of kidney function. The development of chronic kidney disease in HDR patients may be related to both the underlying genetic defect and secondary complications from calcium supplementation.

The genetic counseling implications of HDR syndrome are complex due to its autosomal dominant inheritance with variable penetrance and the evidence for genetic anticipation in some families. The observation that 71.88% of pedigrees show earlier and more severe symptoms in younger generations has important implications for family counseling and surveillance strategies.

Recent advances in genetic testing, particularly next-generation sequencing technologies, have revolutionized the diagnosis of HDR syndrome and enabled the identification of novel mutations and atypical presentations. The discovery of splice site mutations and their functional characterization through minigene experiments represents an important advance in understanding the molecular mechanisms underlying this condition.

Looking toward the future, several research directions hold promise for improving outcomes in HDR syndrome. The development of biomarkers for monitoring disease progression, particularly renal function decline, could enable more proactive management strategies. Gene therapy approaches, while still theoretical, may eventually offer disease-modifying treatments for this transcription factor deficiency.

The study of HDR syndrome also contributes to broader understanding of GATA3 biology and its roles in development and disease. The identification of GATA3 mutations in breast cancer and other malignancies has expanded interest in this transcription factor beyond developmental disorders, potentially leading to new therapeutic insights.

International collaboration through patient registries and research networks will be essential for advancing knowledge about this rare condition. The sharing of clinical data, genetic information, and treatment outcomes across centers worldwide can help establish evidence-based management guidelines and identify prognostic factors.

Healthcare providers should maintain awareness of HDR syndrome as a potential diagnosis in patients presenting with any combination of hypoparathyroidism, sensorineural hearing loss, and renal abnormalities, particularly with a family history suggestive of autosomal dominant inheritance. Early recognition enables appropriate genetic testing, family counseling, and implementation of monitoring strategies to detect and manage complications.

The story of HDR syndrome illustrates the power of clinical observation, genetic analysis, and multidisciplinary collaboration in understanding rare diseases. From its initial description by Barakat and colleagues in 1977 to the current era of precision genetic diagnosis and personalized treatment approaches, this rare syndrome continues to provide valuable insights into human development, gene function, and the complex relationships between genotype and phenotype.

As our understanding of rare genetic disorders continues to evolve, HDR syndrome serves as an important model for studying transcription factor biology, multisystem developmental disorders, and the implementation of personalized medicine approaches in rare disease management. The lessons learned from this condition will undoubtedly contribute to improved care not only for HDR patients but also for individuals with other genetic disorders affecting multiple organ systems.

HDR syndrome

HDR Syndrome: A Comprehensive Medical Review

References

Related Posts:

Recent Post

features

Categories

Weekly Newsletter